What happens when you take carbamazepine with vitamin D?
Carbamazepine (Tegretol, Carbatrol, Equetro, Epitol) is a sodium-channel-blocking anticonvulsant used for focal epilepsy, trigeminal neuralgia, and bipolar disorder. Like phenytoin and phenobarbital, it is a potent inducer of the cytochrome P450 enzyme system, especially CYP3A4 — and that is exactly the system the body uses to break down vitamin D.
Specifically, carbamazepine activates the pregnane X receptor (PXR, also called the steroid and xenobiotic receptor or SXR), which switches on transcription of CYP3A4 and CYP24A1 in the liver and intestine. These enzymes hydroxylate 25-hydroxyvitamin D (the main storage form, also called calcidiol) and the active hormone 1,25-dihydroxyvitamin D into water-soluble inactive metabolites that are then excreted. The effect is dose- and time-dependent: weeks to months of therapy progressively pull serum 25(OH)D downward.
The cascade then proceeds the same way as with phenytoin: low 25(OH)D leads to reduced calcium absorption, falling serum calcium drives a rise in parathyroid hormone (PTH), and the high PTH increases bone turnover and pulls calcium from the skeleton. Clinically this manifests as anticonvulsant-induced osteomalacia, osteoporosis, and increased fracture risk.
Why is this important?
The clinical signal is now well established. A 2006 Epilepsia paper by Mintzer and colleagues found that carbamazepine-treated patients had 25(OH)D levels of roughly 20 ng/mL compared with about 27 ng/mL in matched controls — a clinically meaningful gap. A 2021 meta-analysis of carbamazepine and vitamin D confirmed the consistent direction of effect across multiple populations. Population-level data from large epidemiology cohorts put the fracture risk in long-term enzyme-inducing anticonvulsant users at roughly 1.2 to 2.4 times that of the general population.
Pediatric patients are particularly vulnerable because they are still building peak bone mass. Studies in epileptic children on carbamazepine have documented lower 25(OH)D, higher PTH, higher alkaline phosphatase, and lower bone mineral density compared with non-medicated peers. Adults with limited sun exposure, dark skin, obesity, malabsorption, or institutionalization face the highest risk.
UK regulatory authorities (MHRA) and several national epilepsy guidelines have specifically flagged enzyme-inducing antiepileptics, including carbamazepine, as agents requiring bone-health monitoring in long-term users.
What should you do?
If you are on carbamazepine for more than a few months, ask your prescriber for a baseline 25-hydroxyvitamin D test along with calcium, phosphate, alkaline phosphatase, and ideally PTH. Many neurologists repeat 25(OH)D annually.
Most long-term carbamazepine users will need supplemental vitamin D3 (cholecalciferol). A typical maintenance dose is 1,000 to 2,000 IU per day. Patients with documented deficiency are often started on a higher loading regimen (for example 50,000 IU weekly for 8 to 12 weeks) before transitioning to maintenance. Pair vitamin D with adequate calcium — about 1,000 to 1,200 mg per day from food plus supplements as needed — and encourage weight-bearing exercise and reasonable sun exposure.
After several years of carbamazepine therapy, ask about a DXA bone-density scan, especially if you have other osteoporosis risk factors. Track vitamin D dose, sun exposure, and any musculoskeletal symptoms in Pilora so trends are visible at your next visit.
Which specific products are affected?
The interaction applies to all carbamazepine brands and formulations (Tegretol, Tegretol XR, Carbatrol, Equetro, Epitol, and generics), as well as immediate-release and extended-release products. The closely related drug oxcarbazepine (Trileptal) is a weaker CYP3A4 inducer and shows a smaller but still real effect on vitamin D.
The same mechanism applies to phenytoin, phenobarbital, primidone, and to a lesser extent topiramate. Newer agents like levetiracetam, lamotrigine, and lacosamide are not strong CYP inducers and have not shown the same magnitude of vitamin D depletion in published studies, though long-term data continue to accumulate.
On the supplement side, vitamin D3 (cholecalciferol) is generally preferred over D2 (ergocalciferol) for routine repletion. Calcitriol or alfacalcidol bypass the liver hydroxylation step and are reserved for refractory cases under specialist guidance because they carry a higher risk of hypercalcemia.
The bottom line
Carbamazepine activates pregnane X receptor and induces CYP3A4, accelerating the breakdown of vitamin D into inactive metabolites and producing a measurable drop in 25(OH)D over months of therapy. The downstream consequences — secondary hyperparathyroidism, lower bone density, and higher fracture risk — make annual 25(OH)D monitoring and vitamin D3 supplementation (typically 1,000 to 2,000 IU per day) part of standard long-term care.